Increase in Serotonin-1A Autoreceptors in the Midbrain of Suicide Victims with Major Depression—Postmortem Evidence for Decreased Serotonin Activity

It has been hypothesized that a deficit in serotonin may be a crucial determinant in the pathophysiology of major depression. Serotonin-1A receptors are located on serotonin cell bodies in the midbrain dorsal raphe (DR) nucleus, and the activation of these receptors inhibits the firing of serotonin neurons and diminishes the release of this neurotransmitter in the prefrontal cortex. Repeated treatment with some antidepressant medications desensitizes serotonin-1A receptors in the rat midbrain. The present study determined whether the binding of [3H]8-hydroxy-2-(di-n-propyl)aminotetralin (8-OH-DPAT), an agonist at serotonin-1A receptors, is altered in the midbrain of suicide victims with major depression. Radiolabeling of the serotonin-1A receptor in the DR varied significantly along the rostral-to-caudal extent of the human midbrain. The binding of [3H]8-OH-DPAT to serotonin-1A receptors was increased significantly in the midbrain DR of suicide victims with major depression as compared with psychiatrically normal control subjects. In suicide victims with major depression, the increase in the binding of [3H]8-OH-DPAT to serotonin-1A receptors was detected in the entire DR and specifically localized to the dorsal and ventrolateral subnuclei. Enhanced radioligand binding of an agonist to inhibitory serotonin-1A autoreceptors in the human DR provides pharmacological evidence to support the hypothesis of diminished activity of serotonin neurons in suicide victims with major depression.

[1]  G. M. Halliday,et al.  Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus , 1991, Neuroscience.

[2]  J. Endicott,et al.  [Schedule for Affective Disorders and Schizophrenia (SADS)]. , 1987, Acta psychiatrica Belgica.

[3]  C. Montigny,et al.  Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists , 1996, Trends in Neurosciences.

[4]  C. Montigny,et al.  Acute and long-term effects of antidepressant serotonin (5-HT) reuptake blockers on the efficacy of 5-HT neurotransmission : electrophysiological studies in the rat central nervous system , 1988 .

[5]  Christer Halldin,et al.  PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain , 1997, Psychopharmacology.

[6]  A. Anand,et al.  Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. , 1997, The American journal of psychiatry.

[7]  M. Åsberg,et al.  Suicide Risk and Serotonin , 1992, International clinical psychopharmacology.

[8]  O. Hornykiewicz,et al.  Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. , 1974, Advances in biochemical psychopharmacology.

[9]  V. Pérez,et al.  Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. , 1994, Archives of general psychiatry.

[10]  E. Robins,et al.  Regional serotonin levels in brain: a comparison of depressive suicides and alcoholic suicides with controls. , 1976, Biological psychiatry.

[11]  M. Wood,et al.  [3H]8‐OH‐DPAT labels the 5‐Hydroxytryptamine uptake recognition site and the 5‐HT1A binding site in the rat striatum , 1988, The Journal of pharmacy and pharmacology.

[12]  R. W. Achor,et al.  Depressive Reactions in Hypertensive Patients: A Comparison of Those Treated with Rauwolfia and Those Receiving No Specific Antihypertensive Treatment , 1959, Circulation.

[13]  R. Samanin,et al.  Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors. , 1994, European journal of pharmacology.

[14]  L. DeLisi,et al.  Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims. Comparison in chronic schizophrenic patients with suicide as cause of death. , 1986, Archives of general psychiatry.

[15]  V. Pérez,et al.  Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment , 1997, The Lancet.

[16]  G. Halliday,et al.  Cytoarchitecture of the human dorsal raphe nucleus , 1990, The Journal of comparative neurology.

[17]  T. Kelly,et al.  Validity of DSM‐III‐R diagnosis by psychological autopsy: a comparison with clinician ante‐mortem diagnosis , 1996, Acta psychiatrica Scandinavica.

[18]  E. Smeraldi,et al.  How long should pindolol be associated with paroxetine to improve the antidepressant response? , 1997, Journal of clinical psychopharmacology.

[19]  M. Riad,et al.  Effect of the selective lesion of serotoninergic neurons on the regional distribution of 5-HT1A receptor mRNA in the rat brain. , 1992, Brain research. Molecular brain research.

[20]  J. Sprouse,et al.  Apparent regional differences in 5-HT1A binding may reflect [3H]8-OH-DPAT labeling of serotonin uptake sites , 1993, Brain Research.

[21]  U. Bogdahn,et al.  Reduced echogenicity of brainstem raphe specific to unipolar depression: A transcranial color-coded real-time sonography study , 1995, Biological Psychiatry.

[22]  C. de Montigny,et al.  Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. , 1986, The Journal of pharmacology and experimental therapeutics.

[23]  M. Gobbi,et al.  Effect of acute and chronic administration of buspirone on serotonin and benzodiazepine receptor subtypes in the rat brain: An autoradiographic study , 1991, Neuropharmacology.

[24]  B. Winblad,et al.  DETERMINATION OF MONOAMINE AND MONOAMINE METABOLITES IN THE HUMAN BRAIN: POST MORTEM STUDIES IN A GROUP OF SUICIDES AND IN A CONTROL GROUP , 1976, Acta psychiatrica Scandinavica.

[25]  J. Haycock,et al.  Quantitative subregional distribution of serotonin1A receptors and serotonin transporters in the human dorsal raphe , 1996, Brain Research.

[26]  P. Blier,et al.  Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. , 1995, Journal of clinical psychopharmacology.

[27]  C. Katona,et al.  5-HT1A receptor binding sites in post-mortem brain samples from depressed suicides and controls. , 1997, Journal of affective disorders.

[28]  M. Wilson,et al.  The organization of serotonergic projections to cerebral cortex in primates: Retrograde transport studies , 1991, Neuroscience.

[29]  D. Gallager,et al.  GABAergic subsensitivity of dorsal raphe neurons in vitro after chronic benzodiazepine treatment in vivo , 1988, Brain Research.

[30]  J. Marcusson,et al.  Brain 5-HT1A, 5-HT1D, and 5-HT2 Receptors in suicide victims , 1994, Biological Psychiatry.

[31]  M. Tome,et al.  Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency , 1997, International clinical psychopharmacology.

[32]  Mark A. Smith,et al.  The effect of chronic imipramine administration on the densities of 5-HT1A and 5-HT2 receptors and the abundancies of 5-HT receptor and transporter mRNA in the cortex, hippocampus and dorsal raphe of three strains of rat , 1994, Brain Research.

[33]  R. S. Stacey,et al.  5-hydroxytryptamine, noradrenaline, and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. , 1969, Lancet.

[34]  E. Pinter,et al.  Psychosomatic aspects of catecholamine depletion: Comparative studies of metabolic, endocrine and affective changes , 1976, Psychoneuroendocrinology.

[35]  F. Camps,et al.  5-Hydroxytryptamine in the Hind-Brain of Depressive Suicides , 1967, British Journal of Psychiatry.

[36]  C. Sotelo,et al.  Direct Immunohistochemical Evidence of the Existence of 5‐HT1A Autoreceptors on Serotoninergic Neurons in the Midbrain Raphe Nuclei , 1990, The European journal of neuroscience.

[37]  J. Davis,et al.  Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients. , 1968, Lancet.

[38]  P. Goldman-Rakic,et al.  Serotonergic axons in monkey prefrontal cerebral cortex synapse predominantly on interneurons as demonstrated by serial section electron microscopy , 1996, The Journal of comparative neurology.

[39]  C. Montigny,et al.  Current advances and trends in the treatment of depression. , 1994, Trends in pharmacological sciences.

[40]  R. Bergeron,et al.  Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: are they related? , 1997, International clinical psychopharmacology.

[41]  M. Drake.  Diagnostic and Statistical Manual of Mental Disorders (3rd ed. rev.) , 1988 .

[42]  G. Aghajanian,et al.  (-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists. , 1986, European journal of pharmacology.

[43]  C. Montigny,et al.  Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment , 1989, Synapse.

[44]  R. Fanelli,et al.  Alteration of 5‐HT1A receptor binding sites following chronic treatment with ipsapirone measured by quantitative autoradiography , 1992, Synapse.

[45]  J. Hensler,et al.  A quantitative autoradiographic study of serotonin 1A receptor regulation , 1991 .

[46]  H. Meltzer,et al.  Serotonin Receptors in Suicide Victims with Major Depression , 1997, Neuropsychopharmacology.

[47]  H L Miller,et al.  Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. , 1997, Archives of general psychiatry.

[48]  J. John Mann,et al.  Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims , 1995, Brain Research.

[49]  C. Nemeroff,et al.  Selective serotonin reuptake inhibitors in the treatment of depression , 1996 .

[50]  J. Sweeney,et al.  Attempted Suicide Characteristics and Cerebrospinal Fluid Amine Metabolites in Depressed Inpatients , 1996, Neuropsychopharmacology.